Search Results - Krop, I.E.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

    PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers by Wang, Q, Liu, P, Spangle, J M, Von, T, Roberts, T M, Lin, N U, Krop, I E, Winer, E P, Zhao, J J

    Published in Oncogene
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

    Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer by Grinshpun, A., Ren, S., Graham, N., DeMeo, M.K., Wrabel, E., Carter, J., Tayob, N., Pereslete, A., Hamilton, E., Juric, D., Mayer, E.L., Tolaney, S.M., Krop, I.E., Metzger, O.

    Published in ESMO open
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

    Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer by Marín-Aguilera, M., Jares, P., Sanfeliu, E., Villacampa, G., Hernández-lllán, E., Martínez-Puchol, A.I., Shankar, S., González-Farré, B., Waks, A.G., Brasó-Maristany, F., Pardo, F., Manning, D.K., Abery, J.A., Curaba, J., Moon, L., Gordon, O., Galván, P., Wachirakantapong, P., Castillo, O., Nee, C.M., Blasco, P., Senevirathne, T.H., Sirenko, V., Martínez-Sáez, O., Aguirre, A., Krop, I.E., Li, Z., Spellman, P., Metzger Filho, O., Polyak, K., Michaels, P., Puig-Butillé, J.A., Vivancos, A., Matito, J., Buckingham, W., Perou, C.M., Villagrasa-González, P., Prat, A., Parker, J.S., Paré, L.

    Published in ESMO open
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  4. 4
    and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

    and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling by Cheng, H, Liu, P, Ohlson, C, Xu, E, Symonds, L, Isabella, A, Muller, W.J, Lin, N.U, Krop, I.E, Roberts, T.M, Winer, E.P, Arteaga, C.L, Zhao, J.J

    Published in Oncogene
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer

    A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer by Lin, N. U., Seah, D. S., Gelman, R., Desantis, S., Mayer, E. L., Isakoff, S., DiPiro, P., Krop, I. E., Come, S. E., Weckstein, D., Winer, E. P., Burstein, H. J.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    2118 POSTER A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer

    2118 POSTER A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer by Krop, I.E, Beeram, M, Modi, S, Rabbee, N, Girish, S, Tibbitts, J, Holden, S.N, Lutzker, S.G, Burris, H.A

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: